Lannett (LCI) – Company Press Releases
-
Lannett Company, Inc. Enters Into Restructuring Support Agreement
-
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
-
LANNETT SHARES UPDATE
-
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
-
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
-
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
-
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
-
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
-
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE
-
LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2
-
LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT
-
LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS
-
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
-
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
-
LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24
-
LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
-
LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP
-
LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS
-
LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4
-
LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
-
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE
-
LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14
-
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE
-
LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million
-
LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE
-
LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3
-
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
-
LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
-
Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year Guidance
-
Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3
-
Lannett Commences Marketing Mycophenolate Mofetil For Oral Suspension
-
Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results
-
Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25
-
LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®
-
Lannett Launches Fluvastatin Sodium ER Tablets
-
Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing
-
Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600
-
Lannett Announces Fiscal 2021 Third-Quarter Financial Results
-
Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5
-
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility
-
Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026
-
Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026
-
Lannett Submits ANDA For Generic ADVAIR DISKUS®
-
Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance
-
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
-
Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets
-
Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations
-
Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3
-
Lannett Announces New $30 Million Revolving Credit Facility
-
Lannett Pays Off, In Full, Remaining Term A Loans
Back to LCI Stock Lookup